Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.66 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 4/20 | 0.59 |
| ▸ | CPA1 | P15085 | 4/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.59 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16421158 | 1.00 | MME (0.66) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL14787211 | 1.00 | MME (0.66) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL29937707 | 1.00 | MME (0.66) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL30011374 | 0.97 | MME (0.62) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL29892434 | 0.97 | MME (0.62) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL31025651 | 0.97 | MME (0.62) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL31025582 | 0.97 | MME (0.62) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL30010588 | 0.97 | MME (0.62) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL31733871 | 0.93 | MME (0.64) | MMEMMP2ACECPA1ACE2 | |
| SCHEMBL30010760 | 0.93 | MME (0.57) | MMEMMP2ACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192296-A | Polypeptide compound, pharmaceutical composition and application | 杭州禾泰健宇生物科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118846109-A | FAP-based tumor targeting polypeptide drug conjugate and application thereof | 兰州大学 | 2024-10-29 | — | — | CN | claimed |
| CN-116381105-A | Shennong hundred flower honey characteristic marker and screening method and application thereof | 华中农业大学 | 2023-07-04 | — | — | CN | claimed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250326791-A1 | Peptide-Based Drugs for I.N. Delivery to Brain | NATIONAL INSTITUTES OF HEALTH | 2025-10-23 | — | — | US | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250257095-A1 | METHOD FOR VISIBLE LIGHT-MEDIATED CHEMICAL MODIFICATION OF POLYPEPTIDE AND PROTEIN BASED ON CYSTEINE | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2025-08-14 | — | — | US | disclosed |
| US-12378285-B2 | Cyclic peptides and cyclic peptide conjugates for treating neurological disorders | FLORIDA ATLANTIC UNIVERSITY RESEARCH CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4545545-A1 | VISIBLE LIGHT-MEDIATED CYSTEINE-BASED POLYPEPTIDE AND PROTEIN CHEMICAL MODIFICATION METHOD | Shanghai Jiao Tong University (CN) | 2025-04-30 | — | — | EP | disclosed |
| EP-4514405-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM Isotope Technologies Munich SE (DE) | 2025-03-05 | — | — | EP | disclosed |
| US-11578100-B2 | Cyclic peptides, cyclic peptide conjugates and methods of use thereof | FLORIDA ATLANTIC UNIVERSITY RESEARCH CORPORATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | CUREVAC AG (DE) | 2022-10-25 | — | — | US | disclosed |
| EP-2610338-A1 | METHOD FOR PRODUCING SUBSTANCE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130130317-A1 | METHOD FOR PRODUCING SUBSTANCE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | HNRNPH1, HNRNPH3, SNRPE | MME 1902/4885MMP2 4166/4885ACE 4699/4885 |
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | MME 106/4885MMP2 3126/4885ACE 4209/4885 |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | MME 19/4885MMP2 788/4885ACE 28/4885 |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | MME 299/4885MMP2 1079/4885ACE 1219/4885 |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | MME 106/4885MMP2 3126/4885ACE 4209/4885 |
| US-20250257095-A1 | METHOD FOR VISIBLE LIGHT-MEDIATED CHEMICAL MODIFICATION OF POLYPEPTIDE AND PROTEIN BASED ON CYSTEINE | PTMS, CTH, CISD1 | MME 1398/4885MMP2 2975/4885ACE 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.